Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
A phase 2 trial of Anlotinib in sarcomas, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Overview
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma is a phase 2 interventional study registered as NCT07548177 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 33 participants planned, started 2026-04-02 and due to reach its primary completion in 2027-11. Interventions recorded: Benmelstobart injection combined with Anlotinib hydrochloride capsule.
Similar pages
not linked directly; found by shared links- TrialClinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialClinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialFirst-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Shares Anlotinib and the tag pipeline.
- TrialThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
- TrialA Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.